zileuton has been researched along with Pulmonary Disease, Chronic Obstructive in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albert, RK; Bailey, WC; Casaburi, R; Connett, JE; Cooper, JA; Criner, GJ; Curtis, JL; Dransfield, MT; Han, MK; Harnden, SM; Kim, V; Lazarus, SC; Marchetti, N; Martinez, FJ; McEvoy, CE; Niewoehner, DE; Reilly, JJ; Rice, K; Scanlon, PD; Scharf, SM; Sciurba, FC; Washko, GR; Woodruff, PG | 1 |
| Berger, W; Cairns, CB; De Chandt, MT | 1 |
1 review(s) available for zileuton and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Dermatitis, Atopic; Drug Administration Schedule; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Pulmonary Disease, Chronic Obstructive; Rhinitis | 2007 |
1 trial(s) available for zileuton and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization.
Topics: Aged; Biomarkers; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans; Hydroxyurea; Length of Stay; Leukotriene B4; Leukotriene E4; Lipoxygenase Inhibitors; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Treatment Failure; Treatment Outcome | 2011 |